Indoco Remedies Receives Establishment Inspection Report from USFDA for Patalganga API Facility
Indoco Remedies has received the Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility in Patalganga. The facility was successfully inspected from September 15-19, 2025. This reinforces the company's commitment to quality and compliance.
The USFDA EIR is crucial for continued operations and market access in the United States, positively impacting the company's standing and potential for future business.
The receipt of the Establishment Inspection Report (EIR) from the USFDA is a positive development, indicating successful regulatory compliance for the Patalganga API facility.
Indoco Remedies Limited announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredients (API) manufacturing facility located at Patalganga. This follows a successful inspection of the facility which took place from September 15, 2025, to September 19, 2025.
Ms. Aditi Panandikar, Managing Director of Indoco, expressed pleasure in receiving the EIR, stating that it reinforces the company's commitment to the highest standards of quality and compliance in delivering healthcare solutions worldwide.
Indoco Remedies Limited is a fully integrated, research-oriented pharmaceutical company with a global presence, reporting a turnover of US$ 180 million and employing over 6000 people. The company operates 11 manufacturing facilities (7 for FDFs and 4 for APIs), supported by a state-of-the-art R&D Centre and a CRO facility. Its facilities have received approvals from major regulatory authorities, including the USFDA and UK-MHRA. Indoco manufactures a wide range of pharmaceutical products for both Indian and international markets, generating over 106 million prescriptions annually from a large network of doctors.
What to do with a filing like this
Indoco Remedies Limited filed this with the NSE as a statutory disclosure, categorised under regulatory impact. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indoco Remedies Limited. Read the original for the full detail.